Interview with Tan Yew Chin, Chief Executive Officer, Ascendas
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
Address: 61 Science Park Road, #04-01 The Galen.Singapore Science Park II, Singapore 117525,Singapore
Tel: +65 6774 1033
Web: http://www.ascendas.com/english/
Ascendas is Asia’s leading provider of business space solutions with more than 30 years of experience across the region. Based in Singapore, Ascendas has built a strong regional presence and serves a global clientele of over 2,400 customers in 33 cities across 10 countries including Singapore, China, India, South Korea and Australia.
Ascendas specializes in masterplanning, developing, managing and marketing IT parks, industrial & logistics parks, business parks, science parks, hi-tech facilities, office and retail space for a host of industries. Leveraging on its track record and experience, Ascendas has introduced new business space concepts such as integrated communities and solutions which seamlessly combine high-quality business, lifestyle, retail and hotel spaces to create conducive human-centric work-live-play-learn environments. Its flagship projects include the Singapore Science Park, International Tech Park Bangalore in India, Dalian-Ascendas IT Park in China and Carmelray Industrial Park II in the Philippines.
Asia’s leading provider of business space solutions. The company provides end-to-end real estate solutions, assisting corporate customers through the entire real estate process.
As a pioneering member of Arcasia, before it merged with JTC International and became what is Ascendas today, you know the history of the company very intimately. What are the…
Biotech CRO InvitroCue Executive director Dr. Steven Fang explains how their technology has disrupted the current clinical trials landscape and the importance of leveraging innovative technologies in meeting future healthcare…
Motivated by the transformative role of big data in healthcare, founder and CEO of Vishuo Biomedical, Dongliang Guo discusses the inspiration behind the company, the successful path to commercialization, as well…
Having recently obtained cGMP from Singapore’s Health Sciences Authority, the founders of PrIME Biologics showcase the role of PrIME Technology in driving plasma self-sufficiency in Asia, while highlighting how this…
Director and senior executive officer of Terumo Corporation and managing director of Terumo Asia Holdings, Hideo Arase recounts key takeaways from working in the US medtech market, the unique M&A…
CEO of the Asia Pacific Medical Technology Association (APACMed), Fredrik Nyberg explains the rationale behind the creation of the first regional medical technology association; the industry challenges ahead, and the…
Toshifumi Tada, Managing Director of MT Pharma, shares the significance of Singapore to their presence in the region, the strategic direction of the company to “open up the future,” as…
BD’s Executive VP & President of Greater Asia, James Lim on the concept of “Shared Value” and how this idea has served to advance healthcare systems across the region, while…
Mundipharma’s president of Asia Pacific, Latin America, and the Middle East and Africa, Raman Singh defines the underlying drivers behind the company’s explosive growth, while sharing his insights on what…
The French ambassador to Singapore showcases the importance of the Asian country to France as a regional hub, the footprint of the French business community in the Singaporean economy, and…
Dublin-based Allergan has undergone many changes recently, with the acquisition by Actavis, the failed merger with Pfizer, and the divestiture of the generics business to Teva. The company’s SVP and…
Established in November 2014, Amgen’s Next-Generation Biomanufacturing facility in Singapore heralds a new juncture of efficient and innovative commercial-scale production of medicines. VP of Singapore Site Operations, Arleen Paulino, pinpoints…
With Amgen having recently reacquired the sales rights to three of its drugs, the company’s GM in Singapore and Malaysia, Raphael Ho, explains the rationale behind Amgen’s recent entry in…
See our Cookie Privacy Policy Here
